This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Stocks to Watch: Barnes & Noble, Gen-Probe (Update 1)

Updated with information about Barnes & Noble's deal with Microsoft, Hologic's acquisition of Gen-Probe.

NEW YORK -- Microsoft (MSFT - Get Report) will make a $300 million investment for a 17.6% stake in a new Barnes & Noble (BKS) subsidiary that will bring together the bookseller's digital and college businesses.

The partnership includes a NOOK application for Windows 8, Barnes & Noble and Microsoft said.

Shares of Barnes & Noble soared 72.08% in premarket trading Monday to $23.54. The stock has fallen 5.52% year to date.

Microsoft shares ticked up 21 cents, or 0.66%, in premarket trading to $32.19. The stock has risen 23.19% year to date.

Hologic (HOLX) agreed to acquire Gen-Probe (GPRO) for $82.75 a share in a cash, or about $3.7 billion..

Shares of Gen-Probe rose 19.33% in premarket trading Monday to $82. The stock has risen 16.23% year to date.

Hologic shares increased 4.8% in premarket trading to $22.25. The stock has gained 21.25% year to date.

NYSE Euronext (NYX) said first-quarter adjusted earnings declined 32%.

The exchange saw a slowdown in trading, particularly in its derivatives trading unit, and was hit by costs associated with its failed merger with Germany's Deutsche Boerse.

Adjusted profit in the quarter was 47 cents a share; analysts were looking for 48 cents.

Humana (HUM - Get Report), the health care company, reported first-quarter earnings Monday of $248 million, or $1.49 a share, down from year-earlier earnings of $315 million, or $1.86 a share.

First-quarter earnings included a gain of 3 cents a share from previous medical claim reserves; year-earlier earnings included a gain of 31 cents a share.

Humana was expected by analysts to report first-quarter earnings of $1.52 a share.

Humana raised its full-year 2012 guidance to between $7.55 a share and $7.75 a share from a previous range of between $7.50 a share and $7.70 a share. Analysts were calling for earnings of $7.99 a share.

Shares of Humana fell 4.35% in premarket trading Monday to $84. The stock has risen 0.24% year to date.

Apple's Doomed? More Than One Person Thinks So

Watson Pharmaceuticals (WPI) reported non-GAAP first-quarter earnings Monday of $208.8 million, or $1.64 a share, up from year-earlier earnings of $111.9 million, 89 cents.

Analysts were expecting first-quarter profit of $1.60 a share on revenue of $1.48 billion.

Shares of Watson Pharmaceuticals were flat in premarket trading on Monday. The stock has risen 26.22% year to date.

Watson Pharmaceuticals last week agreed to buy competitor Actavis for $5.6 billion.

Sterling CEO: Small Businesses Fueling Loan Growth

Warner Chilcott (WCRX), the drugmaker, is weighing options including a possible sale after receiving interest from strategic and private-equity buyers, according to people with knowledge of the matter, Bloomberg reported.

Shares of Warner Chilcott gained 15.86% in premarket trading Monday to $21.77.

Pall (PLL) agreed to sell certain blood collection assets to Haemonetics (HAE) for about $550 million.

Haemonetics, the blood component collection device company, reported on Sunday fourth-quarter earnings of $17.8 million, or 69 cents a share, down from year-earlier earnings of $21 million, or 81 cents.

Energy company Anadarko Petroleum (APC - Get Report) is expected by Wall Street analysts to post first-quarter profit of 83 cents a share on revenue of $3.42 billion.

Anadarko reports after the markets close Monday.

10 Ways to Buy a Great Summer at Home

-- Written by Joseph Woelfel

>To contact the writer of this article, click here: Joseph Woelfel

>To submit a news tip, send an email to:

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
NYX $0.00 0.00%
WCRX $0.00 0.00%
APC $52.76 0.00%
HUM $177.07 0.00%
MSFT $49.87 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs